№ lp_1_2_22975
File format: docx
Character count: 30621
File size: 148 KB
This document outlines the biomarkers that must be reported to the Secretary of the Department of Health for the purposes of the Improving Cancer Outcomes (Diagnosis Reporting) Regulations 2025, listing the cancer or cancer precursor biomarkers required by Victorian pathology laboratories.
Year:
2025
Region / city:
Victoria
Subject:
Cancer biomarkers
Document type:
Regulatory document
Organization / institution:
Department of Health
Author:
Unknown
Target audience:
Healthcare professionals, pathology laboratories
Effective date:
18 September 2025
Date of approval:
Unknown
Date of amendments:
Unknown
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2023
Field:
Biomaterials / Polymer Chemistry
Document Type:
Supplementary Material
Institution:
University Research Laboratory
Authors:
Not specified
Target Audience:
Researchers in biomaterials and hydrogel engineering
Methods:
Michael-type addition, photopolymerization, Ellman’s assay, swelling analysis
Compounds:
PEGDA, PEGMA, CysAm, RGD peptide, Eosin Y, TEA, NVP
Experimental Conditions:
pH 7.4, 10 mM PBS, visible light initiation
Equations:
Supplementary Equations 1–8 provided for precursor calculation and network analysis
End-use:
Hydrogel formation for experimental study
Year:
2021
Region / City:
Pirassununga, SP, Brazil
Topic:
Veterinary medicine, animal welfare, swine castration
Document Type:
Research article
Institution:
University of Sao Paulo, North Carolina State University, Washington State University, Michigan State University, Iowa State University, University of Missouri
Author:
Laya Kannan Silva Alves, Monique Danielle Pairis-Garcia, Juliana Bonin Ferreira, Victoria Rocha Merenda, Rubia Mitalli Tomacheski, Pedro Henrique Esteves Trindade, Christopher Siepker, Magdiel Lopez-Soriano
Target Audience:
Researchers, veterinary professionals
Period of Study:
Not specified
Approval Date:
Not specified
Date of Revision:
Not specified
Year:
2023
Program:
Lysosomal Biomarkers Program
Document Type:
Pre-Proposal Template
Intended Audience:
Principal Investigators and Research Teams
Submission Format:
PDF
Institution/Company:
[To be filled by applicant]
Principal Investigator:
[To be filled by applicant]
Project Focus:
Biomarker development, characterization, or validation
Target Disease:
Parkinson’s Disease
Scope:
Experimental plan including rationale, study design, and resource availability
Inclusion Considerations:
Diversity, equity, and inclusion in sample selection
Authors:
Joshua B. Ewen; Claudio Babiloni; Gary S. Collins; Lauren E. Ethridge; Jean Gotman; Akio Ikeda; Philippa J. Karoly; William Z. Potter; Stephan Rampp; Margitta Seeck; Sándor Beniczky
Submitting body:
IFCN Executive Committee
Submission date:
15 July 2024
Organ / Institution:
International Federation of Clinical Neurophysiology (IFCN)
Document type:
Reporting guideline; Explanation and Elaboration document
Field:
Clinical neurophysiology; EEG-based biomarkers
Scope:
Evaluation and reporting of clinical biomarker accuracy studies involving EEG technologies
Related frameworks:
STARD; TRIPOD; EQUATOR Network
Intended use:
Reporting standards across biomarker validation phases (Phase 1–3)
Contexts of Use:
Diagnostic; Monitoring; Response; Predictive; Prognostic; Safety; Susceptibility/Risk
Validation phases described:
Phase 1 (Discovery); Phase 2 (Preliminary validation); Phase 3 (Validation)
Year:
2019
Region / City:
Boston, MA, USA
Topic:
Biomarkers, therapeutic development, clinical trials
Document type:
Article
Organization / Institution:
Harvard Business School, Harvard-MIT Center for Regulatory Science
Author:
Ariel Dora Stern
Target Audience:
Researchers, regulators, the therapeutics industry
Period of validity:
N/A
Approval Date:
May 22, 2019
Funding:
Kauffman Foundation
Running title:
Biomarker ratios for personalized therapeutic decisions
Authors:
Dejana Bajić; Nemanja Todorović; Mladena Lalić Popović; Ljiljana Andrijević
Affiliation:
Department of Biochemistry, Faculty of Medicine, University of Novi Sad; Department of Pharmacy, Faculty of Medicine, University of Novi Sad
Institution:
Institute for Pulmonary Diseases of Vojvodina, Clinic for Intensive Medicine and Vascular Pulmonary Diseases, Department for Intensive Care and Intoxications Level 3
Country:
Serbia
Corresponding author:
Dejana Bajić, MD, PhD
ORCID IDs:
0000-0002-7958-068X; 0000-0002-1519-5643; 0000-0001-8354-3868; 0000-003-0676-7985
Study design:
Retrospective observational clinical study
Study period:
November 2020 – February 2022
Sample size:
133 ICU patients with COVID-19-related sepsis
Primary endpoint:
28-day mortality
Biomarkers analyzed:
Neutrophil-to-lymphocyte ratio (NLR); Fibrinogen-to-albumin ratio (FAR); C-reactive protein-to-albumin ratio (CAR)
Statistical methods:
ROC curve analysis; logistic regression
Ethical approval:
Ethics Committee of the Institute for Pulmonary Diseases of Vojvodina (Protocol Code No. 9-II/3, February 24, 2022); Ethics Committee of the Faculty of Medicine, University of Novi Sad (Protocol Code No. 01-39/190/1)
Conflicts of interest:
None declared
Funding:
No financial support received
Keywords:
biomarkers; COVID-19; inflammation; prognosis
Year:
2026
Region / City:
Ulm, Germany
Theme:
Blood biomarkers, Frailty, Geriatrics
Document Type:
Research Study
Institution:
Ulm University Medical Centre
Author:
Felix Boehm MSc, Lea Fritzenschaft, MD, Stefanie Braig, Michael Denkinger, MD, Dietrich Rothenbacher, MD, Dhayana Dallmeier, MD
Target Audience:
Researchers, Healthcare professionals, Geriatric specialists
Period of Validity:
Not specified
Approval Date:
Not specified
Modification Date:
Not specified
Year:
2026
Region / City:
Beijing
Topic:
Biomarkers, Environmental Science
Document Type:
Research Supplement
Institution:
Peking University
Authors:
Fanrong Zhao, Qiyue Kang, Xiaohua Zhang, Jiaying Liu, Jianying Hu
Target Audience:
Researchers in environmental sciences, toxicology
Period of Validity:
N/A
Approval Date:
N/A
Date of Last Update:
N/A
Contextual Description:
Research supplement detailing the synthesis and analysis of biomarkers for human exposure to flame retardants.
Year:
2023
Region / City:
Europe
Field:
Biomarkers, Clinical Research
Document Type:
Guidelines
Organization:
BioMS-eu
Author:
Michael Khalil
Target Audience:
Researchers, Clinical Laboratories
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Modifications:
Not specified
Context:
This document outlines the procedures and requirements for collaboration in research studies related to biomarkers within the BIOMS-eu network.
Year:
2024
Region / City:
New Zealand
Topic:
Medical research, concussion biomarkers
Document Type:
Consent form
Institution:
Health and Disability Ethics Committee, New Zealand
Principal Investigator:
Professor Patria Hume
Co-Investigators:
Dr Ed Maunder, Professor Alice Theadom, Dr Beth McQuiston, Dr Chris Puliu’vea, Dr Doug King, Dr Stephen Kara, Assoc Prof Mangor Pedersen, Dr Liza Kunz, et al.
Target Audience:
Female research participants
Study Period:
November 2024 – March 2025
Ethics Approval Date:
March 2025
Ethics Reference Number:
HDEC 2024 EXP 21888
Trial Registry:
ANZCTR ACTRN12625000260426
Consent Type:
Informed voluntary participation with options for data use and future contact
Year:
2026
Region / City:
Baltimore, MD, USA; Research Triangle Park, NC, USA; Durham, NC, USA; Chapel Hill, NC, USA
Subject:
Environmental health; Biomonitoring; Heavy metals
Document Type:
Supplementary material
Institution:
Johns Hopkins Bloomberg School of Public Health; National Institute of Environmental Health Sciences; Social & Scientific Systems, Inc.; University of North Carolina Gillings School of Global Public Health
Authors:
Joyce J.Y. Lin, Lily J. Koffman, Mina W. Tehrani, Rui Chen, Dale P. Sandler, Kaitlyn G. Lawrence, W. Braxton Jackson II, Aisha S. Dickerson, Gurumurthy Ramachandran, Lawrence S. Engel, Ana M. Rule
Study Population:
Adult participants aged 20–69, racially diverse
Data Collection Period:
Not specified
Analytical Methods:
ICP-MS gas modes for elemental analysis, log10 transformation, Shapiro-Wilk test for normality
Measured Elements:
Al, Cd, Cu, Fe, Mg, Mn, Pb, Sb, V, Zn, As, Ca, Cr, Ni, Se, Co, Hg, Mo
Sample Type:
Toenail clippings
Figures and Tables:
Distributions of metal concentrations, sub-sample agreement scatterplots, density plots comparing elemental concentrations
Year:
2024
Field:
Oncology, Precision Medicine
Document type:
Review article
Authors:
Bore et al.
Keywords:
ctDNA, CTCs, Extracellular vesicles, Liquid biopsy, Tumour-educated platelets, Precision oncology
Intended audience:
Medical researchers, clinicians
Biological materials analyzed:
Blood, urine, saliva, cerebrospinal fluid, semen
Technologies discussed:
Next-generation sequencing, digital PCR, microfluidic CTC capture
Clinical applications:
Cancer diagnosis, prognosis, treatment monitoring, detection of therapy resistance
Research trends:
Peak in scientific publications in 2024
Note:
Year
Theme:
Medical, Oncology
Document Type:
Referral Form
Organization / Institution:
University Hospitals Birmingham
Target Audience:
Healthcare professionals, GPs
Context:
Form for urgent referral of patients suspected of having urological cancers to appropriate medical specialists.
Year:
2024
Note:
Region / city
Subject:
Urological Cancer Referrals
Document type:
Guidelines
Organization:
UHB (University Hospitals Birmingham)
Target audience:
Healthcare professionals, general practitioners
Effective period:
From April 2024
Keywords:
PSA, DRE, urological cancer, referral, bladder cancer, prostate cancer, biopsy, UTI, urology
Year:
2023
Region / City:
New Zealand
Topic:
Bowel cancer screening, interval cancers, screening sensitivity
Document Type:
Report
Organization:
New Zealand Cancer Registry
Author:
Not specified
Target Audience:
Healthcare professionals, researchers
Period of Validity:
Not specified
Approval Date:
Not specified
Date of Changes:
Not specified
Year:
2019
Region / City:
Not specified
Subject:
Gynecological cancer management
Document type:
Guidelines
Institution:
Not specified
Author:
Not specified
Target audience:
Healthcare professionals in gynecology
Period of validity:
Not specified
Approval date:
Not specified
Revision date:
Not specified
Year:
2025
Region / City:
Westminster
Topic:
Cancer care, governance, NHS, cancer treatment
Document Type:
Work Programme
Organization:
APPG on Less Survivable Cancers
Author:
APPG on Less Survivable Cancers Secretariat
Target Audience:
APPG members, MPs, healthcare professionals
Period of Action:
September 2025 - January 2026
Approval Date:
September 2025
Date of Changes:
Not specified
Context:
This work programme outlines the planned activities and sessions for the APPG on Less Survivable Cancers, focusing on improving cancer care governance, treatment delays, and collaboration with other parliamentary groups.
Version:
4.2.0.0
Protocol Posting Date:
June 2023
Note:
CAP Laboratory Accreditation Program
Protocol Required Use Date:
March 2024
Authors:
Raja R. Seethala, MD; Justin A. Bishop, MD; William C. Faquin, MD, PhD; Shao Hui Huang, MD; Nora Katabi, MD; William Lydiatt, MD; Brian O’Sullivan, MB BCh; Snehal Patel, MD; Jason Pettus, MD; Lindsay Williams, MD
Tumor Types:
Carcinoma, Mucosal Melanoma
Procedures:
Resection
Accreditation Requirements:
Core and conditional data elements required for definitive primary cancer resections
Optional Data Elements:
Identified with “+” for local practice consideration
Excluded Specimens:
Biopsy, primary resection with no residual cancer, cytologic specimens, squamous cell carcinoma in situ
Excluded Tumor Types:
Sarcoma, lymphoma, carcinomas of dry vermillion lip
Reporting Format:
Synoptic reporting of all required data elements
Standards Referenced:
AJCC-UICC 8, WHO 5th edition, pTNM classification
Year:
2023
Note:
Region / city
Subject:
Oncology
Document Type:
Protocol
Organization / Institution:
CAP
Author:
Raja R. Seethala, MD; Justin A. Bishop, MD; William C. Faquin, MD, PhD; Shao Hui Huang, MD; Nora Katabi, MD; William Lydiatt, MD; Brian O’Sullivan, MB BCh; Snehal Patel, MD; Jason Pettus, MD; Lindsay Williams, MD
Target Audience:
Pathologists, medical professionals in oncology
Effective Period:
March 2024
Approval Date:
June 2023
Date of Changes:
June 2023
Year:
2021
Region / City:
Global
Topic:
Smoking, Digestive Cancers, Epidemiology
Document Type:
Research Report
Organization:
Global Burden of Disease Study
Author:
Not specified
Target Audience:
Health professionals, researchers, policymakers
Period of Action:
1990–2021
Date of Approval:
Not specified
Date of Changes:
Not specified